MARKET

RAPT

RAPT

RAPT THERAPEUTICS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.26
-1.28
-6.23%
After Hours: 19.10 -0.16 -0.83% 16:18 01/27 EST
OPEN
20.22
PREV CLOSE
20.54
HIGH
20.37
LOW
19.03
VOLUME
234.06K
TURNOVER
--
52 WEEK HIGH
51.21
52 WEEK LOW
10.52
MARKET CAP
472.93M
P/E (TTM)
-8.5482
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
RAPT Therapeutics' (NASDAQ:RAPT) Shareholders Are Down 28% On Their Shares
It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...
Simply Wall St. · 01/07 09:30
RAPT Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory...
GlobeNewswire · 01/05 13:00
RAPT Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for pat...
GlobeNewswire · 01/05 13:00
5 Value Stocks In The Healthcare Sector
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companie...
Benzinga · 12/28/2020 15:16
Is RAPT A Good Stock To Buy Now?
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was RAPT Therapeutics, Inc....
Insider Monkey · 12/16/2020 04:26
RAPT Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that a webcast of Brian Wong, M.D., Ph.D., President and CEO, and Rodney Young, CFO, participating in a fireside chat in conjunction with the Piper Sandler 32nd Annual Virtual Healthcare Conference will be available today at 10:00 a.m. ET. A replay of RAPT’s fireside chat may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. About RAPT Therapeutics, Inc. RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that are in the discovery stage of development.RAPT Media Contact: Angela Bitting media@rapt.com (925) 202-6211RAPT Investor Contact: Sylvia Wheeler swheeler@wheelhouselsa.com
GlobeNewswire · 11/23/2020 13:00
RAPT Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for pat...
GlobeNewswire · 11/23/2020 13:00
Rainbows and Unicorns: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Analysts Just Became A Lot More Optimistic
Celebrations may be in order for RAPT Therapeutics, Inc. (NASDAQ:RAPT) shareholders, with the analysts delivering a...
Simply Wall St. · 11/23/2020 06:24
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RAPT. Analyze the recent business situations of RAPT THERAPEUTICS, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RAPT stock price target is 36.17 with a high estimate of 51.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 77
Institutional Holdings: 15.99M
% Owned: 65.13%
Shares Outstanding: 24.56M
TypeInstitutionsShares
Increased
21
2.19M
New
26
1.05M
Decreased
16
1.53M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.27%
Pharmaceuticals & Medical Research
-3.25%
Key Executives
President/Chief Executive Officer/Director
Brian Wong
Chief Financial Officer/Primary Contact
Rodney Young
Senior Vice President
Paul Kassner
Chief Scientific Officer
Dirk Brockstedt
Vice President/Director of Human Resources
Phyllis Gray
Vice President
Lisa Moore
Other
William Ho
Director
Peter Svennilson
Independent Director
Michael Giordano
Independent Director
Mary Gray
Independent Director
Linda Kozick
Independent Director
William Rieflin
Independent Director
Wendye Robbins
  • Dividends
  • Splits
  • Insider Activity
No Data
About RAPT
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.

Webull offers kinds of Rapt Therapeutics Inc stock information, including NASDAQ:RAPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RAPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RAPT stock methods without spending real money on the virtual paper trading platform.